Lv1
70 积分 2026-02-26 加入
Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera
2个月前
已完结
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis
3个月前
已完结
Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study
3个月前
已完结
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
3个月前
已完结
Risk stratification of patients with TP53-mutated myeloproliferative neoplasms
3个月前
已完结
Mutations and prognosis in primary myelofibrosis
3个月前
已完结
The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification
4个月前
已关闭
皖公网安备34019202002308
